Xtant Medical received $10.7 million from Companion Spine related to the latter’s purchase of Xtant’s Coflex assets and Paradigm OUS businesses in December 2025, bringing the total aggregate purchase price for the two divestitures to $21.4 million. With this payment, the transactions have now been finalized.
Of the $10.7 million recently received by Xtant, $8.2 million was in satisfaction of the unsecured promissory note issued to Xtant by Companion Spine, plus accrued interest, and an additional $2.2 million related to settlement of working capital and other purchase price adjustments.
Sean Browne, President and CEO of Xtant Medical, stated, “We are very pleased to finalize these transactions with Companion Spine, which place these assets and businesses with a recognized leader in the neuro-musculoskeletal space while allowing us to further sharpen our focus on our higher-margin biologics business. We wish Companion Spine much success in achieving the full market potential of these motion preservation technologies.”
Xtant Medical received $10.7 million from Companion Spine related to the latter's purchase of Xtant's Coflex assets and Paradigm OUS businesses in December 2025, bringing the total aggregate purchase price for the two divestitures to $21.4 million. With this payment, the transactions have now been finalized.
Of the $10.7 million recently...
Xtant Medical received $10.7 million from Companion Spine related to the latter’s purchase of Xtant’s Coflex assets and Paradigm OUS businesses in December 2025, bringing the total aggregate purchase price for the two divestitures to $21.4 million. With this payment, the transactions have now been finalized.
Of the $10.7 million recently received by Xtant, $8.2 million was in satisfaction of the unsecured promissory note issued to Xtant by Companion Spine, plus accrued interest, and an additional $2.2 million related to settlement of working capital and other purchase price adjustments.
Sean Browne, President and CEO of Xtant Medical, stated, “We are very pleased to finalize these transactions with Companion Spine, which place these assets and businesses with a recognized leader in the neuro-musculoskeletal space while allowing us to further sharpen our focus on our higher-margin biologics business. We wish Companion Spine much success in achieving the full market potential of these motion preservation technologies.”
Copy to clipboard 
